Current Report Filing (8-k)
May 04 2016 - 4:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 2, 2016
RXi PHARMACEUTICALS
CORPORATION
(Exact name
of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-54910
|
|
45-3215903
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (508) 767-3861
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On May 2, 2016, RXi Pharmaceuticals Corporation (the
Company) received written notice (the Notification Letter) from the Nasdaq Stock Market, LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule
5550(a)(2) for continued listing on The Nasdaq Capital Market. The Notification Letter was sent following the implementation of a one-for-ten reverse split of the Companys common stock (the Reverse Split), which became effective on
April 18, 2016. Additional information regarding the Reverse Split can be found in the Companys Current Report on Form 8-K filed on April 15, 2016.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
RXi PHARMACEUTICALS CORPORATION
|
|
|
|
|
Date: May 4, 2016
|
|
|
|
By:
|
|
/s/ Geert Cauwenbergh
|
|
|
|
|
|
|
Geert Cauwenbergh, Dr. Med. Sc.
Chief Executive
Officer
|
2
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Apr 2024 to May 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From May 2023 to May 2024